Klinisches Ansprechen eines Plattenepithelkarzinoms der Haut auf periläsionale Hochdosis-Misteltherapie – Fallbericht

Paul Werthmann, Gregor Sträter, Hedda Friesland, Gunver S. Kienle
Article-ID: DMS-20586-DE

  • Login
  • Get Access
  • Export Citation

Hintergrund: Das kutane Plattenepithelkarzinom (CSCC) ist ein häufiger lokal invasiver Hauttumor, der nur selten metastasiert. Die leitliniengerechte Behandlung ist die chirurgische Entfernung, die in den meisten Fällen kurativ ist. Die Behandlung mit Viscum-album-Extrakten (VAE) ist eine weit verbreitete integrativ-medizinische Tumorbehandlung mit immunologischen, apoptogenen und zytotoxischen Effekten, die bisher noch nicht bei CSCC untersucht wurde. Fall-Präsentation: Ein 78-jähriger Patient mit histologisch gesichertem CSCC lehnte eine chirurgische Behandlung ab und wurde mit periläsionaler VAE-Therapie (Abnobaviscum® Fraxini / Betulae) behandelt. Nach 10 Monaten Behandlung hatte sich das CSCC klinisch vollständig zurückgebildet. Der Patient ist seitdem rezidivfrei (für bisher 4 Jahre). Fazit: Der vorgestellte Fall zeigt ein klinisches Ansprechen eines CSCC auf periläsionale VAE-Injektions-Therapie. Weitere Forschung zu VAE-Therapie bei CSCC sollte erfolgen.

Durable response of cutaneous squamous cell carcinoma following high-dose perilesional injections of Viscum album extracts – a case report

Background: Cutaneous squamous cell carcinoma (CSCC) is a common locally invasive skin cancer which rarely metastasises. First-line treatment is surgical excision, which is curative in most cases. Viscum album extract (VAE) is a widely used herbal cancer treatment with cytotoxic, apoptogenic and immunological effects, but has not been investigated in CSCC. Case presentation: A 78-year-old patient with histologically diagnosed CSCC refused surgical excision and was treated with perilesional high-dose VAE (Abnobaviscum ® Fraxini / Betulae). After 10 months of treatment the CSCC had disappeared clinically. The patient has been recurrence-free for 4 years. Conclusion: The presented case shows clinical response of a CSCC to high-dose perilesional VAE injections. Further research on VAE in CSCC is warranted.

1 Madan V, Lear JT, Szeimies RM. Non-melanoma skin cancer. Lancet 2010 Feb 20;375(9715):673–85. [Crossref]

2 English DR, Armstrong BK, Kricker A, Winter MG, Heenan PJ, Randell PL. Demographic characteristics, pigmentary and cutaneous risk factors for squamous cell carcinoma of the skin: a casecontrol study. Int J Cancer 1998 May 29;76(5):628–34. [Crossref]

3 Motley RJ, Preston PW, Lawrence CM. Multi-professional Guidelines for the Management of the Patient with Primary Cutaneous Squamous Cell Carcinoma. London: British Association of Dermatologists; 2009.

4 Rodust PM, Stockfleth E, Ulrich C, Leverkus M, Eberle J. UVinduced squamous cell carcinoma – a role for antiapoptotic signalling pathways. Br J Dermatol 2009 Nov;161 Suppl 3:107–15. [Crossref]

5 Rowe DE, Carroll RJ, Day CL, Jr. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. J Am Acad Dermatol 1992 Jun;26(6):976–90. [Crossref]

6 Marks R. The epidemiology of non-melanoma skin cancer: who, why and what can we do about it. J Dermatol 1995 Nov;22(11):853–7. [Crossref]

7 Karagas MR, Stukel TA, Greenberg ER, Baron JA, Mott LA, Stern RS. Risk of subsequent basal cell carcinoma and squamous cell carcinoma of the skin among patients with prior skin cancer. Skin Cancer Prevention Study Group. JAMA 1992 Jun 24;267(24):3305–10. [Crossref]

8 O’Regan B, Hirshberg C. Spontaneous Remission – An Annotated Bibliography. Institute of Noetic Sciences; 1993.

9 Chodorowski Z, Anand JS, Wisniewski M, Madalinski M, Wierzba K, Wisniewski J. [Spontaneous regression of cancer – review of cases from 1988 to 2006.] Przegl Lek 2007;64(4–5):380–2.

10 Molassiotis A, Fernandez- Ortega P, Pud D, Ozden G, Scott JA, Panteli V, et al. Use of complementary and alternative medicine in cancer patients: a European survey. Ann Oncol 2005 Apr;16(4):655–63. [Crossref]

11 Kienle GS, Kiene H. Die Mistel in der Onkologie – Fakten und konzeptionelle Grundlagen. Stuttgart, New York: Schattauer Verlag; 2003.

12 Büssing A (ed). Mistletoe. The Genus Viscum. Amsterdam: Hardwood Academic Publishers; 2000.

13 Kienle GS, Kiene H. Review article: Influence of Viscum album L (European mistletoe) extracts on quality of life in cancer patients: a systematic review of controlled clinical studies. Integr Cancer Ther 2010 Jun;9(2):142–57. [Crossref]

14 Kienle GS, Kiene H. Complementary cancer therapy: a systematic review of prospective clinical trials on anthroposophic mistletoe extracts. Eur J Med Res 2007 Mar 26;12(3):103–19.

15 Kienle GS, Kiene H. Wirksamkeitsbeurteilung der Misteltherapie – Methodologie und Einzelfälle. In: Kienle GS, Kiene H (ed). Die Mistel in der Onkologie. Stuttgart, New York: Schattauer Verlag; 2003: 433–90.

16 Orange M, Fonseca M, Lace A, von Laue B, Geider S. Durable tumour responses following primary highdose induction with mistletoe extracts: Two case reports. European Journal of Integrative Medicine 2010;1(4):227. [Crossref]

17 Kirsch A. Successful treatment of metastatic malignant melanoma with Viscum album extract (Iscador M). J Altern Complement Med 2007 May;13(4):443–5. [Crossref]

18 Seifert G, Tautz C, Seeger K, Henze G, Laengler A. Therapeutic use of mistletoe for CD30+ cutaneous lymphoproliferative disorder/lymphomatoid papulosis. J Eur Acad Dermatol Venereol 2007 Apr;21(4):558–60.

19 Olaku O, White JD. Herbal therapy use by cancer patients: A literature review on case reports. Eur J Cancer 2010;47(4):508–14. [Crossref]

20 Stein GM. Toxicology of mistletoe and their components. In: Büssing A (ed). Mistletoe. The Genus Viscum. Amsterdam: Hardwood Academic Publishers; 2000: 183–94.

21 Stein GM, Berg PA. Adverse effects during therapy with mistletoe extracts. In: Büssing A (ed). Mistletoe. The Genus Viscum. Amsterdam: Hardwood Academic Publishers; 2000: 195–208.

22 Kienle GS, Grugel R, Kiene H. Safety of higher dosages of Viscum album L. in animals and humans – systematic review of immune changes and safety parameters. BMC Complement Altern Med 2011 Aug 28;11(1):72. [Crossref]

23 Farasat S, Yu SS, Neel VA, Nehal KS, Lardaro T, Mihm MC, et al. A new American Joint Committee on Cancer staging system for cutaneous squamous cell carcinoma: Creation and rationale for inclusion of tumor (T) characteristics. J Am Acad Dermatol 2011 Jan 19. [Crossref]

24 Schleisiek K. Inhaltsstoffe von Abnoba Viscum Fraxini/Betulae. 10-2-2011. Mündliche Mitteilung.

25 Scheffler A, Mast H, Fischer S, Metelmann HR. Komplette Remission eines Mundhöhlenkarzinoms nach alleiniger Mistelbehandlung. In: Scheer R, Becker H, Berg PA (eds). Grundlagen der Misteltherapie. Aktueller Stand der Forschung und klinische Anwendung. Stuttgart: Hippokrates Verlag GmbH; 1996: 453–66.

26 Goodman GE, Hellstrom I, Brodzinsky L, Nicaise C, Kulander B, Hummel D, et al. Phase I trial of murine monoclonal antibody L6 in breast, colon, ovarian, and lung cancer. J Clin Oncol 1990 Jun;8(6):1083-92.

27 Alessi SS, Sanches JA, Oliveira WR, Messina MC, Pimentel ER, Festa NC. Treatment of cutaneous tumors with topical 5% imiquimod cream. Clinics (Sao Paulo) 2009;64(10):961-6. [Crossref]

28 Wacker B, Nagrani T. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 2007 Jul 1;13(13):3913-21. [Crossref]

29 Adams J, Sibbritt D, Lui CW. The urban-rural divide in complementary and alternative medicine use: a longitudinal study of 10,638 women. BMC Complement Altern Med 2011;11:2. [Crossref]

30 Mistry R, Wademan B, Avery G, Tan ST. A case of misdiagnosed squamous cell carcinoma due to alternative medical misadventure – time for tightening regulation? N Z Med J 2010 Apr 9;123(1312):61-7

31 Gagnier JJ, Riley D, Altman DG, Moher D, Sox H, Kienle G. The CARE Guidelines: Consensus-based clinical case reporting guideline development. Deutsches Ärzteblatt International 2013, 110(37):603. [Crossref]

Merkurstab Newsletter
Latest content with links to all articles.
Free of charge. Without obligation.
Open access to selected articles.
Sign up


J O B   M A R K E T

KRANKENHAUS LAHNHÖHE, LAHNSTEIN
Facharzt für Psychosom. Medizin (Chefarzt) (m/w/d) in Vollzeit und
Facharzt für Psychosom. Medizin und Psychotherapie (Stationsarzt, ggf. Oberarzt) (m/w/d) oder
Weiterbildungsassistent (m/w/d) 
Psycholog. Psychotherapeut (m/w/d) in Voll- oder Teilzeit
More details

TROXLER WERKSTÄTTEN, WUPPERTAL
Honorararzt (m/w/d) 
More details

INTEGRATIVE ALLGEMEINMEDIZIN TAUNUSSTEIN
Facharzt für Allgemeinmedizin (m/w/d) 
Weiterbildungsassistent Allgemeinmedizin (m/w/d)
More details